User:Mr. Ibrahem/Gilteritinib

Gilteritinib, sold under the brand name Xospata, is a medication used to treat acute myeloid leukemia (AML). Specifically it is used for cases that have failed other treatments and have a specific mutation in FLT3. It is taken by mouth. It may require six months for benefits to occur.

Common side effects include liver problems, tiredness, diarrhea, nausea, cough, swelling, shortness of breath, low blood pressure, and pain. Other side effects may include differentiation syndrome, arrhythmias, anaphylaxis, and posterior reversible encephalopathy syndrome (PRES). Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor that blocks FLT3.

Gilteritinib was approved for medical use in the United States in 2018, Europe in 2019, and Australia in 2020. In the United Kingdom 4 weeks of treatment costs the NHS about £14,200 as of 2021. In the United States this amount costs about 23,700 USD.